Skip to Content

Neogen Corp NEOG

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Neogen Has Nice Growth in Fiscal Q2, but Supply Chain and Labor Challenges Weigh on Margin

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Narrow-moat Neogen reported decent fiscal second-quarter results with 10% organic sales growth exceeding our expectations, though growth was offset by higher operating costs. We maintain our $24 fair value estimate. We would anticipate a $2 increase to valuation if the U.S. corporate tax rate remains at 21%, however, we would still view shares as materially overvalued even in this scenario.

Read Full Analysis

Company Profile

Business Description

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety (70% of post-merger sales), Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for global food and feed processing companies. In animal safety (20% of post-merger sales), Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for 60% of total revenue, while international markets, including Canada, Europe, Asia, and Latin America, account for the remaining 40%.

Contact
620 Lesher Place
Lansing, MI, 48912
T +1 517 372-9200
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Nov 30, 2021
Fiscal Year End May 31, 2022
Stock Type Slow Growth
Employees 1,841